AbbVie Presents New Phase 3 AFFIRM Data Showing Clinical and Endoscopic Outcomes With Subcutaneous SKYRIZI® (risankizumab-rzaa) in Patients With Moderately to Severely Active Crohn's Disease
AbbVie presented Phase 3 AFFIRM study results showing subcutaneous SKYRIZI® (risankizumab-rzaa) achieved higher endoscopic remission and ulcer-free endoscopy rates in Crohn's disease patients vs. placebo. The data supports FDA approval for a new induction dosing regimen. SKYRIZI is already approved for other immune-mediated diseases.
How this was made
The 30-second read
Why it matters
The disclosed Phase 3 endoscopic remission and ulcer-free endoscopy results, plus the stated intent to apply to the FDA for a subcutaneous induction dosing regimen, are a concrete pipeline and regulatory catalyst for ABBV’s Crohn’s program.
Market read
Traders get a fresh efficacy readout (endoscopic remission and ulcer-free endoscopy) and a stated regulatory next step for ABBV’s Crohn’s dosing strategy.
What to watch
Regulatory outcomes depend on FDA review of the overall benefit-risk package, including comparative efficacy versus existing Crohn’s options and any subgroup limitations not captured in this summary.
Background
AbbVie is evaluating subcutaneous SKYRIZI (risankizumab-rzaa) as an induction option in adults with moderately to severely active Crohn’s disease in the Phase 3 AFFIRM study.
Ticker impact
AbbVie reports Phase 3 AFFIRM Phase 3 results for subcutaneous SKYRIZI in Crohn's, including endoscopic remission and FDA application for SC induction dosing.
Likely upward bias as traders price improved probability of FDA approval for subcutaneous induction dosing based on deeper endoscopic outcomes.
The article discloses specific Phase 3 endoscopic remission and ulcer-free endoscopy rates plus a stated plan to seek FDA approval for the SC induction regimen, which is directly tied to ABBV’s Crohn’s franchise and regulatory timeline.
Market effects
Reinforces IL-23 inhibitor competitive positioning in inflammatory bowel disease by highlighting endoscopic depth with a patient-administered subcutaneous induction approach.
Primarily US biotech/immunology sentiment; limited direct regional spillover beyond large-cap pharma.
Supports global regulatory review momentum (FDA and EMA mentioned), which can influence cross-market expectations for IBD treatment standards.
Counterpoint
Endoscopic endpoints may not fully translate into durable clinical benefit or label expansion; traders may wait for full dataset details and safety durability beyond week 24.
Key entities
- companyAbbVie
Sponsor of the Phase 3 AFFIRM study evaluating subcutaneous SKYRIZI in Crohn’s disease.
- drugSKYRIZI (risankizumab-rzaa)
IL-23 inhibitor whose subcutaneous induction regimen is under regulatory review for Crohn’s.
- clinical_trialAFFIRM
Phase 3 randomized, placebo-controlled study assessing subcutaneous risankizumab induction in moderately to severely active Crohn’s disease.
- regulatorU.S. Food and Drug Administration (FDA)
Regulatory body to which AbbVie plans to seek approval for the subcutaneous induction dosing regimen.